Of those known, 74.7% and 40.8% of patients had grades I/II and III cancer; 28.4%, 50.0%, and 21.6% of patients had stages I, II, and III cancers at diagnosis; and 55.0%, 65.0%, and 42.9% of patients were diagnosed with ER-positive, PR-positive, and HER2-positive cancers, respectively. Here, PGR is linked to cancer.